According to the relevant provisions of the “Measures for the Administration of the Recognition of Hi-tech Enterprises” (Guo Ke Fa Huo [2016] No. 32) and the ” Guidelines for the Administration of the Recognition of Hi-tech Enterprises” (Guo Ke Fa Huo [2016] No. 195), the Zhejiang Provincial Certification Organization is hereby issued 11,899 high-tech enterprises identified in 2022 (see the attachment for the list of enterprises) will be filed and publicized, and the public notice period is 10 working days. TYK Medicines (Zhejiang) was a recognized enterprise (No. 7383).

 

(The picture shows the public list)

 

About TYK Medicines

TYK Medicines is an innovative biotechnology company based in China, facing the global, and focusing on the research and development of international cutting-edge new drugs. The company has established a high-efficiency innovative drug research and development platform, with fully functioned instruments, covering multiple pharmaceutical fields including drug synthesis, biological fermentation, drug analysis, bioanalysis, and formulation research, and is committed to becoming the best domestic and world-class new drug research and development company.

 

 

Since its establishment in 2017, the company has vigorously introduced high-end talents from home and abroad, and as of now, the company has established a world-class R&D and management team with more than 170 team members, including 2 national-level talents, 10 Zhejiang provincial-level talents, 16 returnee doctoral experts with rich experience in new drug R&D of well-known multinational pharmaceutical companies, more than 50 technical backbones, and 80% of the team with master’s degree or above. The team has formed a strong R&D team in the whole industry chain of innovative drug R&D from new drug design, new drug screening, new drug synthesis, and new drug clinical to new drug production, covering many fields such as pharmacology, chemistry, biology, drug formulation, pharmacology, pharmacokinetics, pharmacodynamics, and clinical research.

TYK Medicines team is based on the unmet clinical needs for new drugs for major diseases in China and closely follows the international new drug research and development hotspots. In the past five years, the company has carried out more than 20 targeted anti-tumor new drug projects. Among them, 2 national chemical 1.1 new drug projects have been submitted IND for both China and the United States, and have obtained clinical approval documents from the NMPA and the US FDA; 2 national chemical 1.1 new drug projects have obtained approval from the NMPA and are currently in clinical trials.

 

As of 2022, the Company has applied for 54 new drug-related invention patents and 13 PCT patents, of which 13 invention patents have been granted, 1 US patent has been granted and 1 Japanese patent has been granted.

In addition, TYK Medicines attaches great importance to the construction of provincial and municipal scientific research institutions, and actively participates in national, provincial, and municipal scientific and technological projects. The details are as follows:

In May 2019, the company introduced Yangjie Wu academician of the Chinese Academy of Sciences to set up the academician workstation in Huzhou City.

In October 2019, TYK Medicines’ new drug research and development team was rated as a leading entrepreneurial team in the “South Taihu Lake Elite Program” in Huzhou City. In the same year, the company was awarded as a science and technology-based small and medium-sized enterprise in Zhejiang Province and a national science and technology-based small and medium-sized enterprise.

In 2020, the company’s innovative drug development project was awarded as one of the key R&D projects in Zhejiang Province, a special biomedical project in Huzhou City, and a key technological innovation project (Merit-based project) in Zhejiang Province. 2 of the company’s innovative drug projects were selected as foreign expert projects by the Ministry of Science and Technology of China and 1 innovative drug project was selected as a key technological innovation project in Zhejiang Province in 2021.

In 2021, approved by provincial and municipal departments, TYK Medicines set up Huzhou City New R&D Institution, Huzhou Science and Technology Enterprise Research and Development Center, Zhejiang Province Postdoctoral Workstation, and Zhejiang Province New R&D Institution.

In 2022, TYK Medicines was awarded as Zhejiang Academician Workstation, Zhejiang Leading Innovation Team, and National High-tech Enterprise.